<DOC>
	<DOCNO>NCT01342822</DOCNO>
	<brief_summary>The PROMUS Element™ clinical trial ( PLATINUM-PLUS ) consist randomize controlled trial ( RCT ) European Union ( EU ) enroll approximately 2980 subject ( 2:1 randomization PROMUS Element™ : Xience™ Prime ) Population consecutive , comer reimburse indication per-country All subject screen per protocol require inclusion/exclusion criterion .</brief_summary>
	<brief_title>Trial Assess Everolimus-Eluting Coronary Stent System ( PROMUS Element ) Coronary Revascularization</brief_title>
	<detailed_description>The PLATINUM-PLUS trial investigate broad patient lesion population , CE Mark approve PROMUS Element™ Everolimus-Eluting Coronary Stent System ( PROMUS Element ) , combine Element™ stent ( late generation stent Boston Scientific Corporation [ BSC , Natick , Massachusetts , United States ] ) , everolimus , poly ( n butyl methacrylate ) ( PBMA ) poly ( vinylidene fluoride co hexafluoropropylene ) ( PVDF-HFP ) polymer . The PROMUS Element , receive CE Mark November 3rd 2009 ; currently investigation PLATINUM clinical trial , great promise combine BSC 's novel stent technology everolimus drug polymer demonstrate excellent performance SPIRIT clinical program . PROMUS Element comprise follow key component : everolimus , 2 polymer , Element stent component . The everolimus polymer combination commercially available many country MULTI-LINK VISION™ stent . It manufacture distribute Abbott XIENCE™ V Everolimus Eluting Coronary Stent System ( XIENCE V ) , also distribute BSC identical stent system , also manufacture Abbott , PROMUS™ Everolimus-Eluting Coronary Stent System ( PROMUS ) . The name XIENCE V PROMUS use synonymously within protocol . While PROMUS Element new DES system , constituent part either approve Food Drug Administration ( FDA , i.e. , drug polymer PROMUS , P070015 ) , investigation FDA-approved trial ( i.e. , Element stent component PERSEUS trial , G060237 ) , receive approvable letter FDA . The balloon component material PROMUS Element delivery system use TAXUS Liberté ( P060008 ) , receive approvable letter February 11 , 2008 . The PROMUS Element stent delivery system Apex™ Monorail™ PTCA Dilatation Catheter ( P860019/S208 ) , receive approvable letter October 24 , 2006 . Table 1 compare TAXUS Express2 , TAXUS Liberté , PROMUS Element stent system .</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Coronary Stenosis</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>General Inclusion Criteria 1 . The patient must ≥18 age 2 . Symptomatic ischemic heart disease ( CCS class 14 , Braunwald Class IB , IC , and/or objective evidence myocardial ischemia ) ; 3 . Acceptable candidate CABG ; 4 . The patient willing comply specify followup evaluation ; 5 . The patient legally authorize representative inform nature study , agree provision provide write informed consent , approve appropriate Medical Ethics Committee ( MEC ) . Angiographic Inclusion criterion : 6 . Single multiple native coronary artery saphenous vein graft lesion single multiple vessel ; 7 . Patients multilesion multivessel coronary disease may undergo stag ( plan ) procedure within 30days index procedure . 8 . Reference vessel diameter must ≥2.25 ≤ 4.25 mm visual estimate . 1 . Pregnant nursing subject plan pregnancy period 1 year follow index procedure . Female subject childbearing potential must negative pregnancy test do within 7 day prior index procedure per site standard test ; 2 . Patients antiplatelet and/or anticoagulant therapy contraindicate ; 3 . Patient medical illness ( e.g. , cancer , know malignancy , congestive heart failure , organ transplant recipient candidate ) know history substance abuse ( alcohol , cocaine , heroin etc . ) may cause noncompliance protocol , confound data interpretation associate limited life expectancy ( i.e. , less 1 year ) ; 4 . Patient known hypersensitivity contraindication aspirin , heparin/bivalirudin , clopidogrel/ticlopidine , prasugrel , platinum chromium alloy , everolimus , and/or contrast sensitivity adequately premedicated ; 5 . Patient LVEF &lt; 20 % , cardiogenic shock , hemodynamic compromise require pressor inotropes mechanical support device 6 . Any significant medical condition Investigator 's opinion may interfere patient 's optimal participation study ; 7 . Currently participate another investigational drug device study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Heart disease</keyword>
	<keyword>Coronary Revascularization</keyword>
</DOC>